We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna ETFs to Shine on Vaccine News as Outbreak Worsens
Read MoreHide Full Article
The first company to begin human clinical trials of its coronavirus vaccine candidate in the United States — Moderna (MRNA) — has once again come up with encouraging study data relating to mRNA-1273. National Institutes of Health -appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273 has informed Moderna that with a vaccine efficacy of 94.5%, the trial has met the pre-mentioned statistical parameter in the study protocol for efficacy. Notably, the aforesaid study, which is known as the COVE study, is being conducted in association with the National Institute of Allergy and Infectious Diseases (NIAID). It enrolled more than 30,000 participants in the United States.
Notably, the primary endpoint of the Phase 3 COVE study covers the analysis of COVID-19 cases that were confirmed and adjudicated beginning two weeks after the second dose of vaccine. In fact, this first interim analysis was based on 95 COVID-19 cases, out of which 90 cases were observed in the placebo group versus 5 cases observed in the mRNA-1273 group and delivered a point estimate of vaccine efficacy of 94.5% (p <0.0001), according to the company.
Moderna aims to submit for an Emergency Use Authorization (EUA) with the FDA in the coming weeks based on the above-mentioned interim safety and efficacy data. The company expects to receive the EUA informed by the final safety and efficacy data (with a median duration of at least 2 months). Moderna will also submit applications for approvals to global regulatory agencies.
In order to be prepared for distribution of mRNA-1273, post-receipt of EUA and similar global authorizations, Moderna is working with the U.S. Centers for Disease Control and Prevention (CDC), Operation Warp Speed and McKesson (MCK), a COVID-19 vaccine distributor that has been contracted by the U.S. government, along with global stakeholders.
Moderna anticipates to have around 20 million doses of mRNA-1273 to ship in the United States by the end of this year. It is also on track to produce 500 million to 1 billion doses worldwide in 2021. The American Medical Association also recently issued a Current Procedural Terminology code to report vaccination with mRNA-1273 (code: 91301).
Notably, Moderna has informed about further progress toward the distribution, storage and handling of the vaccine using the existing infrastructure entirely. Going by the latest updates provided by the company, the vaccine candidate is now expected to stay stable at standard refrigerator temperatures of 2° to 8°C (36° to 46°F) for 30 days, up from prior estimate of seven days. Moreover, shipping and long-term storage conditions can be maintained at standard freezer temperatures of -20°C (-4°F) for six months.
Other Vaccine Developers Progressing Well
On Nov 9, Pfizer (PFE) and BioNTech announced the efficacy of their mRNA-based coronavirus vaccine candidate, BNT162b2. According to them, the vaccine was more than 90% successful in preventing COVID-19 in participants without prior evidence of SARS-CoV-2 infection. The results are based on the first interim efficacy analysis conducted on Nov 8, by an external, independent Data Monitoring Committee from the Phase 3 clinical study, per the company.
Going on, Pfizer and BioNTech will keep gathering safety data and currently project that a median of two months of safety data following the second (and final) dose of the vaccine candidate matching the FDA guidance for potential EUA should be available by the third week of November.
Meanwhile, other front runners in vaccine development, AstraZeneca (AZN) working in collaboration with the Oxford University, and Johnson & Johnson (JNJ), have resumed their late-stage coronavirus vaccine trials in the United States.
Moderna ETFs to Gain
The competition to come up with a vaccine is opening up near-term opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to Moderna, which was up 9.5% after the announcement of encouraging vaccine data:
ETFMG Treatments Testing and Advancements ETF (GERM - Free Report)
This fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. Focused on advancements with targeted exposure to the forefront of R&D, vaccines, therapies and testing technologies. It holds 63 stocks in its basket, with Moderna occupying the top spot at 8.7% share. The fund has amassed $55 million in its asset base and charges 68 basis points (bps) in annual fees (read: Coronavirus-Themed ETFs in Focus as the Pandemic Worsens).
Principal Healthcare Innovators Index ETF (BTEC - Free Report)
This fund invests in companies that are leading the charge toward innovative solutions, rather than spending money on marketing and distribution by tracking the Nasdaq Healthcare Innovators Index. It holds 262 stocks in its basket, with Moderna taking the top spot at 3.9%. BTEC charges 42 bps in annual fees and has AUM of $121.4 million.
The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 7.5% exposure to Moderna. Its AUM is $471.8 million and it has an expense ratio of 0.35% (read: How Will Biotech ETFs React to These Q3 Earnings Release?).
iShares Genomics Immunology and Healthcare ETF (IDNA - Free Report)
The fund seeks investment results, before fees and expenses, which match the NYSE FactSet Global Genomics and Immuno Biopharma Index. It holds about 46 securities in its basket with Moderna, occupying a weight of 5.6%. It has AUM of $175.4 million and an expense ratio of 0.47% (read: ETFs in Focus on Bayer's Bet on Gene Therapy).
Other broader biotech ETFs that hold companies developing tests, vaccines and therapies for coronavirus include:
This fund seeks to provide exposure to U.S. biotechnology and pharmaceutical stocks and tracks the Nasdaq Biotechnology Index. It has an AUM of $9.66 billion with an expense ratio of 0.46% (read: Here's Why Healthcare ETFs Are Rallying Post Elections).
The fund seeks daily investment results, before fees and expenses, which match the S&P Biotechnology Select Industry Index. It has AUM of $6.49 billion and an expense ratio of 0.35%.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna ETFs to Shine on Vaccine News as Outbreak Worsens
The first company to begin human clinical trials of its coronavirus vaccine candidate in the United States — Moderna (MRNA) — has once again come up with encouraging study data relating to mRNA-1273. National Institutes of Health -appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273 has informed Moderna that with a vaccine efficacy of 94.5%, the trial has met the pre-mentioned statistical parameter in the study protocol for efficacy. Notably, the aforesaid study, which is known as the COVE study, is being conducted in association with the National Institute of Allergy and Infectious Diseases (NIAID). It enrolled more than 30,000 participants in the United States.
Notably, the primary endpoint of the Phase 3 COVE study covers the analysis of COVID-19 cases that were confirmed and adjudicated beginning two weeks after the second dose of vaccine. In fact, this first interim analysis was based on 95 COVID-19 cases, out of which 90 cases were observed in the placebo group versus 5 cases observed in the mRNA-1273 group and delivered a point estimate of vaccine efficacy of 94.5% (p <0.0001), according to the company.
Moderna aims to submit for an Emergency Use Authorization (EUA) with the FDA in the coming weeks based on the above-mentioned interim safety and efficacy data. The company expects to receive the EUA informed by the final safety and efficacy data (with a median duration of at least 2 months). Moderna will also submit applications for approvals to global regulatory agencies.
In order to be prepared for distribution of mRNA-1273, post-receipt of EUA and similar global authorizations, Moderna is working with the U.S. Centers for Disease Control and Prevention (CDC), Operation Warp Speed and McKesson (MCK), a COVID-19 vaccine distributor that has been contracted by the U.S. government, along with global stakeholders.
Moderna anticipates to have around 20 million doses of mRNA-1273 to ship in the United States by the end of this year. It is also on track to produce 500 million to 1 billion doses worldwide in 2021. The American Medical Association also recently issued a Current Procedural Terminology code to report vaccination with mRNA-1273 (code: 91301).
Notably, Moderna has informed about further progress toward the distribution, storage and handling of the vaccine using the existing infrastructure entirely. Going by the latest updates provided by the company, the vaccine candidate is now expected to stay stable at standard refrigerator temperatures of 2° to 8°C (36° to 46°F) for 30 days, up from prior estimate of seven days. Moreover, shipping and long-term storage conditions can be maintained at standard freezer temperatures of -20°C (-4°F) for six months.
Other Vaccine Developers Progressing Well
On Nov 9, Pfizer (PFE) and BioNTech announced the efficacy of their mRNA-based coronavirus vaccine candidate, BNT162b2. According to them, the vaccine was more than 90% successful in preventing COVID-19 in participants without prior evidence of SARS-CoV-2 infection. The results are based on the first interim efficacy analysis conducted on Nov 8, by an external, independent Data Monitoring Committee from the Phase 3 clinical study, per the company.
Going on, Pfizer and BioNTech will keep gathering safety data and currently project that a median of two months of safety data following the second (and final) dose of the vaccine candidate matching the FDA guidance for potential EUA should be available by the third week of November.
Meanwhile, other front runners in vaccine development, AstraZeneca (AZN) working in collaboration with the Oxford University, and Johnson & Johnson (JNJ), have resumed their late-stage coronavirus vaccine trials in the United States.
Moderna ETFs to Gain
The competition to come up with a vaccine is opening up near-term opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to Moderna, which was up 9.5% after the announcement of encouraging vaccine data:
ETFMG Treatments Testing and Advancements ETF (GERM - Free Report)
This fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. Focused on advancements with targeted exposure to the forefront of R&D, vaccines, therapies and testing technologies. It holds 63 stocks in its basket, with Moderna occupying the top spot at 8.7% share. The fund has amassed $55 million in its asset base and charges 68 basis points (bps) in annual fees (read: Coronavirus-Themed ETFs in Focus as the Pandemic Worsens).
Principal Healthcare Innovators Index ETF (BTEC - Free Report)
This fund invests in companies that are leading the charge toward innovative solutions, rather than spending money on marketing and distribution by tracking the Nasdaq Healthcare Innovators Index. It holds 262 stocks in its basket, with Moderna taking the top spot at 3.9%. BTEC charges 42 bps in annual fees and has AUM of $121.4 million.
VanEck Vectors Biotech ETF (BBH - Free Report)
The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 7.5% exposure to Moderna. Its AUM is $471.8 million and it has an expense ratio of 0.35% (read: How Will Biotech ETFs React to These Q3 Earnings Release?).
iShares Genomics Immunology and Healthcare ETF (IDNA - Free Report)
The fund seeks investment results, before fees and expenses, which match the NYSE FactSet Global Genomics and Immuno Biopharma Index. It holds about 46 securities in its basket with Moderna, occupying a weight of 5.6%. It has AUM of $175.4 million and an expense ratio of 0.47% (read: ETFs in Focus on Bayer's Bet on Gene Therapy).
Other broader biotech ETFs that hold companies developing tests, vaccines and therapies for coronavirus include:
iShares Nasdaq Biotechnology ETF (IBB - Free Report)
This fund seeks to provide exposure to U.S. biotechnology and pharmaceutical stocks and tracks the Nasdaq Biotechnology Index. It has an AUM of $9.66 billion with an expense ratio of 0.46% (read: Here's Why Healthcare ETFs Are Rallying Post Elections).
SPDR S&P Biotech ETF (XBI - Free Report)
The fund seeks daily investment results, before fees and expenses, which match the S&P Biotechnology Select Industry Index. It has AUM of $6.49 billion and an expense ratio of 0.35%.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>